Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM024335
Első szerző:Terzano, Claudio
Cím:Beclomethasone dipropionate versus budesonide inhalation suspension in children with mild to moderate persistent asthma / C. Terzano, L. Allegra, L. Barkai, G. Cremonesi
Dátum:2000
Megjegyzések:Inhaled steroids are the most effective long-term treatment of persistent asthma but many children are unable to use correctly the available inhalers. Administration of nebulized corticosteroids has some advantages over the administration with pressurised metered-dose inhalers (pMDIs). The objective of this multicenter randomised study was to compare the efficacy and tolerability of nebulized corticosteroids in paediatric patients with asthma. 127 patients aged ?6 and ? 14 years with a diagnosis of mild to moderate persistent asthma (PEFR % predicted > 50% and < 85%) and positive response to the reversibility test were randomized. The patients were assigned by randomisation to one of the two treatment groups (4 weeks): beclomethasone dipropionate (BDP) 800 ?g/daily b.i.d. (n=66) or budesonide (BUD) 1000 ?g/daily b.i.d. (n=61) both administered by nebulizer. The primary efficacy end point was the final mean of PEFR measured at clinical visit (clinic PEFR). In the BDP group clinic PEFR increased from 177.5 ? 80 L/min to 246.6 ? 84.2 L/min (p<0.001vs baseline), while in the BUD group the increase was from 180.4 ? 77.8 L/min to 260.9 ? 84.1 L/min (p<0.001 vs baseline) (NS between treatments). FEV<sub>1</sub> (% predicted) increased from 77.8% to 92.7% (p<0.001 vs baseline) and from 74.1% to 95.9% (p<0.001 vs baseline) in BDP and BUD group respectively (NS between treatments). Patients reduced the use of salbutamol rescue medication by 76% and 81% in BDP and BUD group respectively (p<0.001 vs baseline, NS between treatments). 4 patients in the BDP group and 2 in the BUD group reported adverse events (AEs). AEs were mild to moderate and never there was the need to discontinue the treatments. In conclusion the results of this study demonstrate that both BDP (800 ?g/daily) and BUD (1000 ?g/daily) administered by nebulization are effective and with a acceptable safety and tolerability profile.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
SUSPENSIONS
Statistics, Nonparametric
Male
Humans
Female
Confidence Intervals
Child
Chi-Square Distribution
Budesonide
Bronchodilator Agents
Beclomethasone
Asthma
Anti-Asthmatic Agents
Analysis of Variance
Adolescent
Administration, Inhalation
suspension
sinusitis
randomized controlled trial
peak expiratory flow
otitis
nebulization
multicenter study
medical nebulizer
major clinical study
human
hoarseness
Forced Expiratory Volume
drug tolerability
drug safety
drug formulation
drug efficacy
drug delivery system
controlled study
controlled clinical trial
clinical trial
ARTICLE
allergic rhinitis
salbutamol
prednisone
leukotriene receptor blocking agent
cromoglycate disodium
corticosteroid derivative
cholinergic receptor blocking agent
bronchodilating agent
beta adrenergic receptor blocking agent
beta 2 adrenergic receptor stimulating agent
beclometasone dipropionate
antihistaminic agent
Nebulized drugs
Beclomethasone dipropionate
Megjelenés:European Review for Medical and Pharmacological Sciences. - 5 : 1 (2000), p. 17-24. -
További szerzők:Allegra, L. Barkai László (1958-) (gyermekgyógyász) Cremonesi, G.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Szerző által megadott URL
Borító:
Rekordok letöltése1